STRENGTHENING EVIDENCE THROUGH HEALTH RESEARCH WHERE MOST PEOPLE ACCESS HEALTHCARE, RACGP joins consortium and calls for practice-based research network in primary health
With
Dr Michael Wright GP, President
The Royal Australian College of General Practitioners (RACGP) &
Associate Professor,
International Centre for Future Health Systems (ICFHS)
Australian Health Journal segment
Filmed in Sydney | March 2025
In February 2025, the Australian Government committed over $22 million for primary care research, including $5.2m awarded to Professor Michael Kidd, Director of the International Centre for Future Health Systems at UNSW and recently appointed Australia’s Chief Medical Officer, to lead the establishment of one of the largest research collaborations in Australia focused on improving primary care.
The Royal Australian College of GPs says a new national multidisciplinary consortium for primary care research is a positive step forward to improve patient care.
The RACGP is a member of the National Multidisciplinary Primary Care Research, Policy and Advocacy Consortium, which involves 100 primary care researchers from 20 universities from across the country.
RACGP President Dr Michael Wright said: “Every year more than 22 million Australians see a specialist GP for their essential health care, making general practice is the most accessed part of our health system.
“Yet research in general practice is vastly underrepresented and underfunded. General practice receives less than 2% of our national medical research funding.
“This new consortium is an important and exciting opportunity to design, test and innovate models of care to better meet the needs of patients across Australia, and I’m proud the RACGP is a member.
“The RACGP is calling for all political parties to commit to funding a national practice-based research network, like they have in Canada and the United Kingdom.
“These networks have proven to be immensely valuable overseas.
“We’re also calling for funding to test how multidisciplinary practice teams work at full scope in Australia, in order to improve access to care for patients.
“We know people get the best outcomes when their GP works together with their other specialists, and health professionals, and it’s especially valuable for people with chronic and complex illnesses.
Source: Highlights from RACGP media release
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
-
Imperatives for women diagnosed with ovarian cancer
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
-
Report gives insights to clinical trial activity in Australia
Established in 2024, Bellberry is a Adelaide-based national, not-for-profit organisation that provides streamlined scientific and ethical reviews of human research. It is the 2025 winner of the Championing Health Award in the Telstra Best of Business Awards.
Australian Health Journal spoke with Bellberry Limited CEO, Kylie Sproston on the organisation and the findings in activity documented in the Clinical Trial Activity Report (CTAR) 2024.
